What targeted therapies are available for CLL

Targeted Therapies for CLL: An Educational Overview

I'm glad you're learning about the treatment options available for chronic lymphocytic leukemia. Targeted therapies have transformed CLL treatment by focusing on specific proteins or pathways that cancer cells depend on. Let me explain the main categories and how they work.

How Doctors Think About Targeted Therapy for CLL

Oncologists approach CLL treatment by identifying what makes the cancer cells "tick"—what proteins or pathways they rely on to survive. Rather than using chemotherapy that damages all rapidly dividing cells, targeted therapies are like precision tools that attack specific vulnerabilities in the leukemia cells while sparing more healthy cells.

---

Main Categories of Targeted Therapies

1. BTK Inhibitors (BTKis)

These drugs target a protein called Bruton's tyrosine kinase (BTK), which CLL cells need to survive and grow.

Types include:

• Ibrutinib (first-generation BTKi)
• Acalabrutinib (second-generation BTKi)
• Zanubrutinib (second-generation BTKi)
• Pirtobrutinib (non-covalent BTKi—a newer approach)

According to NCCN Guidelines for CLL, BTK inhibitors are widely used as first-line treatment options and have demonstrated significant effectiveness in controlling disease.

2. BCL2 Inhibitors

These drugs target a protein called BCL2 that prevents cancer cells from dying naturally.

• Venetoclax is the primary BCL2 inhibitor used in CLL

According to NCCN Guidelines, venetoclax requires careful initiation with a gradual dose ramp-up (starting at 20 mg and increasing over 5 weeks to 400 mg daily) along with tumor lysis syndrome (TLS) prevention. This precaution is important because when many leukemia cells die quickly, they can release contents that harm the kidneys.

3. PI3K Inhibitors

These target phosphatidylinositol 3-kinase (PI3K), another pathway CLL cells use to survive.

• Idelalisib
• Duvelisib

According to NCCN Guidelines, these require close monitoring for liver toxicity and serious infections, so they're typically reserved for specific situations.

4. Anti-CD20 Monoclonal Antibodies

These are immunotherapy drugs that mark CLL cells for destruction by the immune system.

• Rituximab
• Obinutuzumab
• Ofatumumab

These are often combined with other targeted therapies for better results.

5. CAR T-Cell Therapy

This is a more advanced approach where your own immune cells are engineered to recognize and attack CLL cells.

• Lisocabtagene maraleucel (Jcar019)

According to NCCN Guidelines, in real-world analysis of patients with transformed CLL, lisocabtagene maraleucel resulted in an overall response rate of 76%, with manageable side effects in most patients.

---

How These Are Used

For newly diagnosed patients: BTK inhibitors or venetoclax-based combinations are typically first-line options.

For relapsed/refractory CLL (disease that returns or doesn't respond to initial treatment): Different BTKis, venetoclax combinations, or CAR T-cell therapy may be considered.

In combination: According to NCCN Guidelines, these targeted therapies are often combined—for example, a BTKi plus venetoclax, or a BTKi plus an anti-CD20 antibody—to improve effectiveness.

---

Important Questions to Ask Your Oncologist

1. Which targeted therapy approach do you recommend for my specific CLL, and why?
2. What are the expected side effects, and how will we monitor for them?
3. How long would I typically stay on this therapy?
4. What happens if my CLL stops responding to this treatment?
5. Are there clinical trials available that might be appropriate for my situation?

---

Key Takeaway

The targeted therapy landscape for CLL has expanded significantly, offering multiple effective options. Your oncologist will determine the best approach based on your specific disease characteristics (including genetic markers), your age, overall health, and other factors. According to NCCN Guidelines, the choice of therapy should be individualized to maximize both effectiveness and quality of life.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.